Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial

Vexiau, P.; Chaspoux, C; Boudou, Philippe; Fiet, Jean; Jouanique, C.; Hardy, Noah; Reygagne, P.

doi:10.1046/j.1365-2133.2002.04798.x

Cited by 168 publications

(106 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This chemical, after it is converted to its active form (minoxidil sulfate), opens the ATP-dependent potassium channels in cells, causing a vasodilatation effect by increasing the production of vascular endothelial growth factor (VEGF) in dermal papillae, stimulating hepatocyte growth factor (HGF) production and activating the synthesis of prostaglandins, which are mechanisms that ultimately lead to stimulation of hair growth. 28 Other therapeutic options include combination therapy. An interesting alternative was proposed recently by Vinaixa et al, who subjected non-obese women with PCOS to 3-month flutamide-metformin-pioglitazone polytherapy combined with ester-progestogen treatment, pointing to the benefit of such treatment with respect to the lipid profile (reduced LDL, increased HDL) higher androgen levels as well as increased carotid intima media (CIM) thickness, which in turn prevents the occurrence of atherosclerosis and related complications.…”

Section: New Therapeutic Optionsmentioning

confidence: 99%

The pathogenesis and treatment of polycystic ovary syndrome: What’s new?

Bednarska¹,

Siejka²

2017

Adv Clin Exp Med

228

148

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is currently the leading cause of menstrual complications in women. It is characterized by clinical and/or biochemical hyperandrogenism, ovulation abnormalities and the presence of enlarged and/or polycystic ovaries in ultrasound images (12 or more small bubbles located circumferentially and/or ovarian volume > 10 mL). It is often comorbid with hyperinsulinemia, dyslipidemia, overweight or obesity, and is a risk factor for the development of diabetes and cardiovascular diseases (CVDs). The treatment of patients with PCOS depends on the prevailing symptoms. The aim of this paper is to present the etiopathogenesis, clinical and biochemical implications, and non-pharmacological and pharmacological treatment options -those approved by worldwide scientific organizations as well as new therapies whose initial results are encouraging enough to prompt researchers to explore them further.

show abstract

Section: New Therapeutic Optionsmentioning

confidence: 99%

The pathogenesis and treatment of polycystic ovary syndrome: What’s new?

Bednarska¹,

Siejka²

2017

Adv Clin Exp Med

228

148

View full text Add to dashboard Cite

show abstract

“…Although cyproterone acetate is prescribed in Europe to treat FPHL, [6][7][8] its efficacy is still controversial. A controlled 12-month randomized trial 9 compared the effects of cyproterone acetate, 52 mg/d, with 2% topical minoxidil in FPHL. All the patients took oral contraceptives.…”

mentioning

confidence: 99%

Finasteride Treatment of Female Pattern Hair Loss

Iorizzo¹,

Vincenzi²,

Voudouris³

et al. 2006

Arch Dermatol

111

View full text Add to dashboard Cite

“…The 5a-reductase inhibitor (a testosterone conversion blocker) finasteride does not appear to be effective, at least in postmenopausal women (at a dose of 1 mg). [15][16][17] The oral anti-androgens (androgen receptor antagonists) spironolactone [18] and cyproterone acetate (alone or when given in combination with an estrogen) [18][19][20] have been shown to be effective in limiting the progression of hair loss or improve hair growth, and have been used off-label for many years despite a lack of evidence from well-designed studies. The use of anti-androgens requires the use of good contraception because of the risk of feminization of a fetus.…”

Section: Discussionmentioning

confidence: 99%

Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders

Vázquez

Amayuelas

Lamarca

et al. 2011

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

The diagnosis and management of four cases of dermatological disorders, most of which are related to the endocrine disorder of androgen excess, are presented. Combined oral contraceptives (COCs) may be useful when well-tolerated hormonal therapy and or when contraception is required. A female patient with androgenetic alopecia or female pattern balding, without underlying hyperandrogenism, was treated with ethinylestradiol chlormadinone acetate (EE CMA) 0.03 mg 2 mg for 6 months and experienced stabilization of hair loss (case report 1). A patient who had previously received a COC for an irregular menstrual pattern but again experienced irregular menses and also acne after stopping treatment was diagnosed with acne associated with polycystic ovary syndrome (PCOS) [case report 2]. After 6 month's treatment with EE CMA 0.03 mg 2 mg, this patient had fewer acne lesions and became eumenorrheic. A third patient who had excess hair since childhood was diagnosed with idiopathic hirsutism (no underlying gynecological or endocrinological disorder was found) and was treated with EE CMA 0.03 mg 2 mg (case report 3). Less hair growth was reported after 6 months' treatment. Case report 4 describes a patient who presented with oligomenorrhea and acne. She was diagnosed with PCOS with acne, seborrhea and mild hirsutism. Treatment with EE CMA 0.03 mg 2 mg for 6 months resulted in improvements in her facial acne, seborrhea and hirsutism; she also became eumenorrheic. These four cases illustrate that EE CMA may be a useful and well tolerated treatment option in the management of patients with dermatological disorders with or without hyperandrogenization.

show abstract

Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial

Cited by 168 publications

References 22 publications

The pathogenesis and treatment of polycystic ovary syndrome: What’s new?

The pathogenesis and treatment of polycystic ovary syndrome: What’s new?

Finasteride Treatment of Female Pattern Hair Loss

Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders

Contact Info

Product

Resources

About